Trial result

KRAS Has a New Contender. It Still Has to Earn Its Place.

Migraine Prevention Gets a Wider Door

China’s Biliary-Cancer Bet Has a Global Access Problem

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

A CE Mark Is Not Access

ALS Needs Proof, Not Just Another Biomarker

The Transplant Is Not the Finish Line

For Pompe Infants, Time Is the Comparator

Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
